- Home
- PRLD vs XFOR Comparison
PRLD vs XFOR Comparison
Compare PRLD & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | XFOR |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.1M | 377.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRLD | XFOR |
|---|---|---|
| Price | $3.84 | $3.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.67 | ★ $9.00 |
| AVG Volume (30 Days) | 484.2K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.75 | $1.35 |
| 52 Week High | $5.69 | $4.83 |
Technical Indicators
Market Signals| Indicator | PRLD | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 46.79 |
| Support Level | $3.40 | $3.54 |
| Resistance Level | $4.13 | $4.09 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 3.85 | 30.98 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.